ASH 2023 – Barbara Eichhorst

Barbara F. Eichhorst describes possible approaches to improve the early detection of molecular CLL relapses, discusses venetoclax-based first-line combinations in CLL, and rates the relative efficacy and safety of different BTK inhibitors in relapsed/refractory CLL while finally sharing her personal highlights from the ASH 2023 congress.

Here is the full ASH 2023 report.